Data From Two High-Dose Chemo/Transplant Studies to Be Released

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

BETHESDA, Md-The National Cancer Institute (NCI) announced that preliminary findings from two long-awaited breast cancer studies are expected to be made available April 15 on the American Society of Clinical Oncology (ASCO) website (www.asco.org).

BETHESDA, Md—The National Cancer Institute (NCI) announced that preliminary findings from two long-awaited breast cancer studies are expected to be made available April 15 on the American Society of Clinical Oncology (ASCO) website (www.asco.org).

The two NCI-sponsored studies address the effectiveness of high-dose chemotherapy and autologous bone marrow or stem cell transplants in the treatment of breast cancer. NCI said more fully analyzed data from the two studies would be presented at the ASCO meeting in Atlanta, May 15–18, along with results from two similar European studies.

NCI made its announcement after a meeting with researchers, ASCO representatives, and patient advocacy groups called to determine when reliable data could be released.

Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Related Content